Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia

Preeclampsia Clinical Trial

Official title: Serum LncRNAs as Early Potential Biomarkers for the Prediction of Preeclampsia

Status Recruiting

Clinical Trial Summary

To identify lncRNAs differentially expressed at early stages of gestation in the serum of pregnant women, who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with normal pregnancy .

Clinical Trial Description

Preeclampsia (PE) is a pregnancy syndrome characterized by hypertension and proteinuria, and a leading cause of maternal and fetal morbidity and mortality, with poorly defined pathophysiological mechanisms remain. Circulating lncRNAs are long, noncoding RNA molecules, which negatively regulate gene expression, and considered as promising biomarkers for PE. The objective of the study is to evaluate circulating lncRNA signatures in women with PE compared to healthy women, and in women sub-grouped per PE severity. This study assessed lncRNA expression profile in the serum at early stages of gestation of women who later developed severe preeclampsia (sPE) in the third trimester of pregnancy compared to women with uncomplicated pregnancies. Circulating lncRNA was extracted from maternal serum. This study also assess lncRNA expression profile in the placenta tissues of PE patients and healthy pregnant women. ;

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

• NCT number: NCT03903393
• Study type: Observational
• Source: First Affiliated Hospital of Harbin Medical University
• Contact: Yue Li, MD
• Phone: 86-451-85555673
• Email: ly99ly@vip.163.com
• Status: Recruiting
• Start date: March 31, 2019
• Completion date: March 2021